Profile

NeuMedics was founded in Washington State in 2008.  It is a development stage biopharmaceutical company focused on the rapid development of therapies to treat Diabetic Macular Edema (DME) and related inflammatory conditions.

Neumedics lead compound NM108

• is a proprietary compound.
• is non-steroidal,
• non-mAb
• eye drop
• a novel mechanism-of-action
• and can be self-administered by patients.